<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">METHIMAZOLE</span><br/>(meth-im'a-zole)<br/><span class="topboxtradename">Tapazole<br/></span><b>Classifications:</b> <span class="classification">hormones and synthetic substitutes</span>; <span class="classification">antithyroid agent</span><br/><b>Prototype: </b>Propylthiouracil<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 10 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Thioamide with actions and uses similar to those of propylthiouracil but 10 times as potent. Actions are less consistent,
         but effects appear more promptly than with propylthiouracil. Inhibits synthesis of thyroid hormones as the drug accumulates
         in the thyroid gland. Does not affect existing T<sub>3</sub> or T<sub>4</sub> levels.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Corrects hyperthyroidism by inhibiting synthesis of the thyroid hormone.</p>
<h1><a name="uses">Uses</a></h1>
<p>Hyperthyroidism and prior to surgery or radiotherapy of the thyroid; may be used cautiously to treat hyperthyroidism in pregnancy.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Pregnancy (category D), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Other drugs known to cause agranulocytosis.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hyperthyroidism</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 515 mg q8h<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 0.20.4 mg/kg/d divided q8h<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give at same time each day relative to meals.</li>
<li>Store at 15°30° C (59°86° F) in light-resistant container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">GI:</span>
<span class="speceff-life">hepatotoxicity (rare)</span>. <span class="typehead">Endocrine:</span> Hypothyroidism. <span class="typehead">Hematologic:</span>
<span class="speceff-common">Leukopenia,</span> agranulocytosis, granulocytopenia, thrombocytopenia, pancytopenia, and aplastic anemia. <span class="typehead">Musculoskeletal:</span> Arthralgia. <span class="typehead">CNS:</span> Peripheral neuropathy, drowsiness, neuritis, paresthesias, vertigo. <span class="typehead">Skin:</span> Rash, alopecia, skin hyperpigmentation, urticaria, and pruritus. <span class="typehead">Urogenital:</span> Nephrotic syndrome. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Can reduce anticoagulant effects of <b>warfarin;</b> may increase serum levels of <b>digoxin;</b> may alter <b>theophylline</b> levels; may need to decrease dose of <span class="classification">beta-blockers</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Onset:</span> 3040 min. <span class="typehead">Peak:</span> 1 h. <span class="typehead">Duration:</span> 24 h. <span class="typehead"> Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead">Elimination:</span> 12% excreted in urine within 24 h. <span class="typehead">Half-Life:</span> 513 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Periodic blood work, since agranulocytosis is a rare, but possible adverse effect.</li>
<li>Closely monitor PT and INR in patients on oral anticoagulants. Anticoagulant activity may be potentiated.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Adhere to established dosage regimen (i.e., not to double, decrease, or omit doses and not to alter the interval between doses).</li>
<li>Be aware that skin rash or swelling of cervical lymph nodes may indicate need to discontinue drug and change to another antithyroid
            agent. Consult physician.
         </li>
<li>Notify physician promptly if the following symptoms appear: Bruising, unexplained bleeding, sore throat, fever, jaundice.</li>
<li>Drug-induced jaundice may persist up to 10 wk after withdrawal of drug.</li>
<li>Methimazole does not induce hypothyroiditis.</li>
<li>Do not breast feed while using this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>